Reduction of tumour blood flow by vasoactive drugs: a role in cancer therapy.
The potential use of tumour blood flow reductions, induced by the vasodilator hydralazine, in cancer therapy are described. Data obtained in experimental tumour systems indicate that with appropriate scheduling and drug combinations, hydralazine can increase the therapeutic effectiveness of certain chemotherapeutic agents whether used alone or in combination with other modalities such as radiation or hyperthermia.
Chaplin
D J
DJ
Medical Biophysics Unit, B.C. Cancer Research Centre, Vancouver, Canada.
Acker
B D
BD
Horsman
M R
MR
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D002699:Chlorambucil / Q000627:therapeutic use; D006830:Hydralazine / Q000627:therapeutic use*; D006979:Hyperthermia, Induced; D008175:Lung Neoplasms / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply* / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D051379:Mice; D008809:Mice, Inbred C3H; D012039:Regional Blood Flow / Q000187:drug effects; D014410:Tumor Stem Cell Assay
D002699:Chlorambucil; D006830:Hydralazine